KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Return on Equity (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Return on Equity data on record, last reported at 1.41% in Q4 2025.

  • For Q4 2025, Return on Equity fell 214.0% year-over-year to 1.41%; the TTM value through Dec 2025 reached 1.41%, down 214.0%, while the annual FY2025 figure was 1.41%, 307.0% down from the prior year.
  • Return on Equity reached 1.41% in Q4 2025 per AMRX's latest filing, down from 0.52% in the prior quarter.
  • Across five years, Return on Equity topped out at 5.52% in Q1 2024 and bottomed at 1.62% in Q1 2023.
  • Average Return on Equity over 5 years is 0.11%, with a median of 0.05% recorded in 2021.
  • Peak YoY movement for Return on Equity: soared 714bps in 2024, then plummeted -578bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.05% in 2021, then plummeted by -2605bps to 1.35% in 2022, then skyrocketed by 58bps to 0.56% in 2023, then skyrocketed by 230bps to 0.73% in 2024, then plummeted by -294bps to 1.41% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 1.41% in Q4 2025, 0.52% in Q3 2025, and 0.42% in Q2 2025.